Core Insights - Hoth Therapeutics reported positive preclinical data indicating that HT-VA restores cholesterol levels and improves lipid metabolism in a model of metabolic dysfunction associated with obesity and MASLD [1] Group 1: Study Findings - The second phase of the study evaluated serum liver biochemistry and hepatic molecular pathways in female mice fed a western diet, showing that GDNF improved lipid metabolism biomarkers compared to controls and Semaglutide [1] - GDNF treatment restored cholesterol concentrations to levels comparable with control diet-fed mice, indicating improved lipid metabolism [1] - GDNF-treated mice maintained lower triglyceride levels, while Semaglutide increased triglycerides, demonstrating a more favorable lipid profile for GDNF [1] Group 2: Liver Function and Autophagy - Analysis showed no significant change in alkaline phosphatase (ALP) or albumin (ALB) levels across treatment groups, indicating stable liver synthetic function [1] - GDNF treatment did not increase p62 expression, while Semaglutide increased p62 levels, suggesting GDNF preserved normal cellular recycling pathways in the liver [1] Group 3: Molecular Signaling - No changes in CD36 or PPAR expression were observed in GDNF-treated mice, indicating improved metabolic biomarkers without activating lipogenic pathways [1] - Semaglutide treatment resulted in increased phosphorylation of AKT (pAKT) in liver tissue, while GDNF did not significantly alter pAKT signaling, highlighting a distinct molecular signaling profile [1] Group 4: Study Design - The study design included evaluation of serum liver biochemistry and hepatic protein expression related to lipid metabolism, autophagy, and apoptosis over four weeks of treatment with GDNF, Semaglutide, or vehicle [1]

Core Insights - Hoth Therapeutics Inc. has revealed promising preclinical data on glial cell-derived neurotrophic factor (GDNF) for obesity and metabolic-associated steatotic liver disease (MASLD), supported by the U.S. Veterans Administration [1][3] - GDNF has shown superior efficacy compared to semaglutide in key metrics such as weight stabilization, glucose tolerance, liver weight reduction, and adipose tissue control, particularly in female models [2][5] - The obesity market is valued at $200 billion, and GDNF's differentiated mechanism may address limitations of current GLP-1 agonists, potentially revolutionizing treatment paradigms for over 1 billion people affected by obesity and 30% of adults impacted by MASLD [3] Study Highlights - In female mice on a high-fat diet, GDNF reduced weight gain by 10-15%, leading to a plateau in weight during treatment, while semaglutide showed no significant impact [4] - GDNF normalized fasting glucose levels and improved glucose response, outperforming semaglutide in females, with additional benefits observed in males [5] - GDNF reduced liver weight by 20-30% and prevented adipose tissue accumulation in females, surpassing the effects of semaglutide [5] Future Directions - Future analyses will focus on liver pathology, lipid content, and gene/protein expression to further understand GDNF's mechanisms [6] - Hoth plans to accelerate GDNF towards IND-enabling studies, with clinical trials targeted for 2027 [6] - Hoth's pipeline includes other programs such as HT-001 for cancer-related skin toxicities, HT-KIT for mast cell cancers, and HT-ALZ for Alzheimer's [6] Market Reaction - Hoth Therapeutics shares increased by 1.83% to $0.87 during premarket trading [8]